COVID-19 Vaccine Safety and Efficacy in Hematopoietic Stem Cell Transplantation (HSCT) Patients

Strategic Insights -

Pfizer BioNTech's mRNA COVID-19 vaccine, BNT162b2, has been prospectively evaluated for safety and immunogenicity in a group of 25 Japanese allogeneic HSCT patients, who received the vaccine in comparison with 19 healthy volunteers. The study found that the vaccine was safe and effective in these patients, with 76% of them experiencing seroconversion of anti-S1 IgG. While the median optical density of antibody levels in HSCT patients with low IgG levels was lower than in healthy volunteers, there were no serious adverse events or exacerbation of graft-versus-host disease after vaccination.

Key Takeaways:

  • The BNT162b2 mRNA COVID-19 vaccine was found to be safe and effective in Japanese allogeneic HSCT patients, with 76% of them experiencing seroconversion of anti-S1 IgG.
  • Median optical density of antibody levels in HSCT patients with low IgG levels was lower than in healthy volunteers.
  • There were no serious adverse events (Grade 3) or new development or exacerbation of graft-versus-host disease after vaccination in HSCT patients.
  • The study's results suggest that the BNT162b2 mRNA vaccine may be a viable option for HSCT patients to prevent COVID-19 infection.
  • The study had a relatively small sample size, with only 25 HSCT patients participating.
  • The study's findings are limited to Japanese allogeneic HSCT patients and may not be generalizable to other populations.

Statistics:

  • 76% of HSCT patients experienced seroconversion of anti-S1 IgG after receiving the BNT162b2 mRNA vaccine.
  • 19 patients (76%) out of 25 HSCT patients got seroconversion after the second dose.
  • Median optical density of antibody levels in HSCT patients with low IgG levels was lower than in healthy volunteers.
  • No serious adverse events (Grade 3) were reported in HSCT patients after vaccination.
  • No new development or exacerbation of graft-versus-host disease was reported in HSCT patients after vaccination.

Sources:

  • medrxiv.org/content/10.1101/2021.12.28.21268477v1
  • Keywords: Biomedicine, Viral, Surgery, Vaccines, Virology, Mortality, RNA Viruses, Immunization, Stem Cell Research, Biological Products, Health and Medicine, Risk and Prevention, Transplant Medicine, Cell Transplantation, COVID-19/SARS-CoV-2 News from Preprints, Severe Acute Respiratory Syndrome Coronavirus 2.